Nascent, Catalent sign product development agreement
As part of the agreement, Catalent will engineer a cell line expressing Nascent’s Pritumumab antibody using Catalent’s GPEx technology. Catalent will produce purified monoclonal antibody to support Nascent’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.